Does Dr. NEERAJ AGARWAL have financial conflicts of interest?

Dr. NEERAJ AGARWAL (MD) has received a total of $151,281 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $53,561 in personal promotional payouts (consulting, meals, travel) and $97,720 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. NEERAJ AGARWAL?

According to CMS Open Payments data, Dr. NEERAJ AGARWAL received funding from PFIZER ($115,147), EXELIXIS ($22,817), and ASTELLAS PHARMA GLOBAL DEVELOPMENT ($3,090).

Does Dr. NEERAJ AGARWAL receive research grants or speaking fees?

Dr. NEERAJ AGARWAL has received $53,561 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $97,720 in clinical research grants.

DR. NEERAJ AGARWAL

MDReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: SALT LAKE CITY, UT 84112

NPI Number: 1417078221

LIFETIME INDUSTRY VALUE

$151,281

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AGARWAL is a verified Internal Medicine, Hematology & Oncology practitioner based in SALT LAKE CITY, UT.

Between 2021 and 2024, Dr. AGARWAL had an overall industry promotional and research financial footprint of $151,281 as recorded in the federal CMS Open Payments database.

$53,561 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$97,720 was allocated to sponsored clinical trials and medical research activities.

Dr. AGARWAL's primary funding source is PFIZER, which accounts for $115,147 (representing 76.1% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

PFIZER

Rank 1

$115,147

76.1%

EXELIXIS

Rank 2

$22,817

15.1%

ASTELLAS PHARMA GLOBAL DEVELOPMENT

Rank 3

$3,090

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.